Menopause is an important life event for a woman that
signifies the end of her reproductive era and transitioning into a period of
increasing health risk from cardiovascular disease, osteoporosis, and other
chronic diseases.
According to a census in 1998, there were more than 477
million postmenopausal women in the world, and the number is going to rise to
approximately 1.1 billion by 2015. Life expectancy for women worldwide was 65
years in 1998 which has currently increased to 73.2 years (81 years in
developed countries). With increasing
life expectancy women spend one third of life in this phase of life.
In the year 2000, there were an estimated 45.6 million
postmenopausal women in the United
States, out of which about 40 million were
older than age 51, the average age of natural menopause in the Western world.
According to a book chapter by Dr. JoAnn E. Manson, MD, DrPH professor of
medicine at Harvard
Medical School
and Brigham and Women's Hospital “Aging of the female reproductive system
begins at 20 weeks gestation with regard to follicle atresia and proceeds as a
continuum. It consists of a steady loss of oocytes from atresia or ovulation,
and does not necessarily occur at a constant rate. Because of the relatively
wide age range (40-58 y) for natural menopause, chronologic age is a poor
indicator of the beginning or the end of the menopause transition.
This article is based on a
perspective by JoAnn E. Manson,
M.D., Dr.P.H., and Andrew M. Kaunitz, M.D. in March 03, 2016 edition of
The New England Journal of Medicine( NEJM).
Menopausal symptoms are well tolerated by some women, but
may be very troublesome to other women. Often there is underreporting of
menopausal symptoms due to cultural taboos. The attitude towards menopause
varies according to culture and ethnicity, with 80% African women reporting
symptoms versus very few Asian women reporting symptoms.
There has been an ongoing confusion regarding the findings
of WHI study and prescription of hormonal therapy to relieve the symptoms of menopause.
The Women's Health Initiative (WHI) was launched in 1991 and
consisted of a set of clinical trials and an observational study, which
together involved 161,808 generally healthy postmenopausal women.
The clinical trials were designed to test the effects of postmenopausal
hormone therapy, diet modification, and calcium and vitamin D supplements on
heart disease, fractures, and breast and colorectal cancer. The trials were
specifically designed to address questions about effect of initiating menopausal
hormone therapy for the prevention of chronic disease in postmenopausal women
across a broad range of ages, including many women in their 60s and 70s?
In 2002, the study results ripped the widely held belief that hormone
replacement therapy protected women from heart disease and other chronic illnesses.
Instead, the Women's Health Initiative
study found concluded that taking estrogen plus progestin hormone replacement
therapy — HRT — actually increased a woman's risk of heart disease and breast
cancer.
Within months of the results, number of women using HRT dropped by half.
The results of the study were extrapolated to women in 40s and 50s who had
severe vasomotor symptoms disrupting quality of life. In-fact, these women had trouble
finding clinician who could prescribe them with HRT.
But, studies conducted during Extended Poststopping Phases
of the Women’s Health Initiative Randomized Trials when broken down according to age groups
showed entirely different outcomes. Subgroup analysis stratified according to
age and time since menopause onset modified
the effect of HRT on some of the outcomes. The study concluded that HRT is a reasonable option for the management of
moderate to severe menopausal symptoms among generally healthy women during
early menopause.
In-fact, the USPSTF in its
recommendation made a specific mention that “This recommendation applies only to postmenopausal women
who are considering hormone therapy for the primary prevention of chronic
medical conditions. This is not a recommendation about the use of hormone
therapy to treat menopausal symptoms, such as hot flashes or vaginal dryness;
the USPSTF did not review the evidence related to this possible indication
because it falls outside of the mission and scope of the USPSTF. This
recommendation also does not apply to women younger than 50 years who have had
surgical menopause”.
The North American Menopause Society (NAMS), the Endocrine
Society, the American
College of Obstetricians
and Gynecologists (ACOG) endorse the use of HRT in younger women for treating
postmenopausal symptoms, who do not have specific contraindication for the
therapy.
This will definitely improve the quality of life and it is
quite likely that the benefit would outweigh the risks.
These organizations have many resources that help clinicians
in decision making, the NAMS
have a
MenoPro Mobile App, which helps in personalization of
treatment to individual patient and help patient in shared decision making.
The MenoPro app has several unique features, including
the ability to calculate your 10-year risk of heart disease and stroke,
which is important in deciding whether a treatment option is safe for
you. It also has links to online tools that assess your risk of breast
cancer and osteoporosis and fracture.
 |
| Photo courtesy: NAMS |
Finally Dr. JoAnn E. Manson emphasized the need of training
young healthcare providers to keep up with the variety of options in treating
postmenopausal women. This will certainly help in improving the quality of life
of a growing population.
References:
Manson JE, Kaunitz A. Menopause management: getting clinical
care back on track. N Engl J Med. 2016;374:803-806.
.
